A study of nasopharyngeal carcinoma (NPC) treated with celecoxib and ZD1839 [gefitinib].
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Celecoxib (Primary) ; Gefitinib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 30 Mar 2012 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 30 Mar 2012 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
- 30 Mar 2012 Status changed from recruiting to completed as reported by ClinicaiTrials.gov.